XML 22 R55.htm IDEA: XBRL DOCUMENT
v2.4.0.8

License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail) (USD $) In Thousands, unless otherwise specified | 12 Months Ended
--- | ---
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011
License And Collaboration Agreements [Line Items] |  |  |
License, collaboration and other revenue | $ 80,872 | $ 30,127 | $ 36,289
AstraZeneca AB [Member] | Naloxegol (NKTR-118) and Naloxegol Fixed-dose Combination Program (NKTR-119) [Member] |  |  |
License And Collaboration Agreements [Line Items] |  |  |
License, collaboration and other revenue | 25,016 | 59 | 2,496
Roche [Member] | PEGASYS and MIRCERA [Member] |  |  |
License And Collaboration Agreements [Line Items] |  |  |
License, collaboration and other revenue | 18,382 | 7,146 | 5,131
Bayer Healthcare LLC [Member] | BAY41-6551 (Amikacin Inhale) [Member] |  |  |
License And Collaboration Agreements [Line Items] |  |  |
License, collaboration and other revenue | 15,293 | 2,971 | 2,992
Affymax, Inc. [Member] | OMONTYS [Member] |  |  |
License And Collaboration Agreements [Line Items] |  |  |
License, collaboration and other revenue | 7,149 | 2,829 | 3,838
Amgen, Inc. [Member] | Neulasta [Member] |  |  |
License And Collaboration Agreements [Line Items] |  |  |
License, collaboration and other revenue | 5,035 | 5,000 | 5,000
Baxter Healthcare [Member] | BAX 855 (Hemophilia) [Member] |  |  |
License And Collaboration Agreements [Line Items] |  |  |
License, collaboration and other revenue | 1,702 | 6,238 | 5,646
Other [Member] |  |  |
License And Collaboration Agreements [Line Items] |  |  |
License, collaboration and other revenue | $ 8,295 | $ 5,884 | $ 11,186

X
- Details
Name: | nktr_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix: | nktr_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees. + References No definition available. + Details
Name: | nktr_LicenseCollaborationOtherRevenue
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration